CTOs on the Move

Harvard Vanguard Medical Associates

www.harvardvanguard.org

 
At Harvard Vanguard Medical Associates, our staff is our most important resource. That's why we offer challenging work, career advancement, competitive salaries and a benefits program that is among the best in the marketplace. The following summary is
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details

Similar Companies

The Fertility Partners

Founded in March 2019, the objective of The Fertility Partners (“TFP”) is to be a world class business partner of choice for leading North-American IVF clinicians with the goal of achieving global best clinical outcomes, an international reputation for excellence and exceptional patient experiences. TFP will provide partner clinics with back office support and a collaborative synergistic medical-scientific, professional and business environment.

Park Dental Research Corp

Park Dental Research Corp is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Secure Doc Imaging

Secure Doc Imaging is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

St James Plaza

Skilled nursing home providing rehabilitation, long term care, and specialized dementia care in St. James, NY

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.